Hypoxia
Recent clinical, regulatory, research and industry developments relating to this disease.
Microglia regulate motor neuron plasticity via reciprocal fractalkine and adenosine signaling.
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer.
Changes in immune cell populations during acclimatization to high altitude.
The Role of Oxygen Homeostasis and the HIF-1 Factor in the Development of Neurodegeneration.
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
Immune consequences of exercise in hypoxia: A narrative review.
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions.
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q3 2027.
- Q3 2027A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Q4 2027Role of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent Hypoxia
Clinical MilestonesViewHide
- 2026-05-22A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Results expected Q3 2027
- 2026-05-01Role of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent HypoxiaResults expected Q4 2027
- 2025-09-30Intravenous Iron Prophylaxis for Rapid High Altitude InsertionsPrimary completion
- 2026-05-22ClinicalA Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Results expected Q3 2027
- 2026-05-01ClinicalRole of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent HypoxiaResults expected Q4 2027
- 2025-09-30ClinicalIntravenous Iron Prophylaxis for Rapid High Altitude InsertionsPrimary completion
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Hypoxia7
- Neoplasms4
- Signal Transduction4
- Colorectal Neoplasms3
- Neovascularization, Pathologic2
- Acclimatization1
- Adaptive Immunity1
- Adenosine1
Leading journals6
- International journal of molecular sciences3
- The Journal of clinical investigation2
- The Journal of neuroscience : the official journal of the Society for Neuroscience2
- The Journal of physiology2
- Advanced healthcare materials1
- Ageing research reviews1
Leading researchers8
- Burtscher J2
- Burtscher M2
- Millet GP2
- Adam V1
- Al-Badran SSF1
- Albucher JF1
- Alexander PG1
- Alvarez A1
Affiliations (unnormalised)6
- Institute of Sport Sciences2
- School of Medicine2
- University of Innsbruck2
- University of Missouri2
- Beth Israel Deaconess Medical Center1
- Bioelectronics Materials and Devices Laboratory1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Hypoxia is a state of sub-optimal oxygen availability in the ambient air of living organisms. The supplied literature also treats hypoxia as a biologically important condition that shapes metabolism, pathology, immunology, genetics, etiology, and physiopathology across multiple disease contexts.
The grounding supports low ambient oxygen as the defining cause of hypoxia. It also indicates that hypoxia can arise in specific disease settings such as solid tumors, ischemia/reperfusion injury, and COVID-19-related respiratory failure, but it does not provide a broader causal list.
Hypoxia alters signal transduction, homeostasis, autophagy, adaptive immunity, neuronal plasticity, and the tumor microenvironment. The grounding also links hypoxia to hypoxia-inducible factor 1 alpha, cytokines, receptors, and endoplasmic reticulum stress, with ER stress capable of triggering cell death when prolonged or severe.
Low oxygen in the surrounding environment is the clearest risk factor supported by the grounding. The literature also associates hypoxia with altitude and with hypoxic tumor microenvironments, but it does not support a broader general risk-factor profile.
The supplied grounding supports oxygen as the principal treatment modality. In cancer-related hypoxia, the literature also discusses tumor vasculature normalization, nanoparticle carriers, biocarriers, hypoxia tracers, hypoxia-activated prodrugs, and other drugs targeting hypoxia-related pathways as therapeutic approaches.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Sub-optimal OXYGEN levels in the ambient air of living organisms.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.